[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M: Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer; 2010 Aug 1;127(3):543-54
Hazardous Substances Data Bank. RHODANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
  • Phosphatase of regenerating liver-3 (PRL-3) is a molecule associated with metastasis in a diverse of cancers, which, however, remains largely unknown in esophageal squamous cell carcinoma (ESCC).
  • We examined both the clinical significance of PRL-3 expression and its biological roles, and assessed possibilities as a therapeutic target in ESCC.
  • PRL-3 expression was found in 78% (69 of 88) of the primary ESCC on immunohistochemistry; it was the strong independent predictor for lymph node metastasis (LNM) on a multivariate logistic regression model (p = 0.0014, relative risk =15.20).
  • PRL-3 inhibitor (1-4-bromo-2-benzylidene rhodanine) also suppressed such metastatic properties in the cell lines with PRL-3 overexpression, but not with its low expression.
  • Collectively, PRL-3 overexpression is a frequent event associated with LNM and plays a causative role in promoting cancer progression.
  • Moreover, the expression status may be a landmark to select patients with benefit from PRL-3-targeted therapy.
  • Thus, PRL-3 could be a convergent therapeutic target against ESCC with LNM.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Enzyme Inhibitors / pharmacology. Esophageal Neoplasms / drug therapy. Lymphatic Metastasis / physiopathology. Neoplasm Proteins / antagonists & inhibitors. Protein Tyrosine Phosphatases / antagonists & inhibitors. Rhodanine / analogs & derivatives
  • [MeSH-minor] Apoptosis. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Fluorescent Antibody Technique. Gene Expression Regulation, Enzymologic / drug effects. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Multivariate Analysis. Polymerase Chain Reaction. RNA, Small Interfering

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960436.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(2-bromobenzyloxy)-4-bromo-2-benzylidene rhodanine; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 7O50LKL2G8 / Rhodanine; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


2. Takahashi H, Arimura Y, Yamashita K, Okahara S, Tanuma T, Kodaira J, Hokari K, Tsukagoshi H, Shinomura Y, Hosokawa M: Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol; 2010 Jan;5(1):122-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
  • INTRODUCTION: More effective regimens are urgently needed for squamous cell carcinoma of esophagus (SCCE), therefore, we conducted a phase I/II trial of a combination of docetaxel, platinum, and fluorouracil (TPF) for treating metastatic SCCE.
  • CONCLUSIONS: A TPF regimen against metastatic SCCE was well tolerated and achieved a favorable objective response rate and survival benefit compared with other recently reported regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898259.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J: A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. Chin J Cancer; 2010 Mar;29(3):321-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
  • This study was to evaluate the efficacy and toxicity of docetaxel plus nedaplatin and 5-fluorouracil (DNF regimen) in treating advanced esophageal carcinoma.
  • METHODS: Forty-three patients with pathologically confirmed advanced esophageal carcinoma treated by DNF regimen: intravenous infusion of docetaxel (75 mg/m(2)) over 1 h, intravenous infusion of nedaplatin (100 mg/m(2)) over 3 h, intravenous infusion of leucovorin (CF, 200 mg/m(2)) over 2 h, intravenous injection of 5-fluorouracil (375 mg/m(2)) over 10 min, followed by a 46-hour infusion of 5-fluorouracil (2.6 g/m(2)).
  • Treatment efficacy was evaluated every two weeks according to the WHO standards.
  • All patients received at least two cycles of chemotherapy.
  • RESULTS: Patients received a total of 144 cycles of treatment, and all were evaluable for efficacy and toxicity.
  • The median time-to-progression (TTP) was 201 days and the median survival time (MST) was 310 days.
  • CONCLUSION: DNF regimen is effective for and well tolerated by patients with advanced esophageal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Remission Induction. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193118.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Zhang XD, Shen L, Li J, Li Y, Li J, Zhang XT, Jin ML: [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):474-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
  • OBJECTIVE: To investigate the time to progression (TTP) and overall survival in patients with previously untreated metastatic or relapsed esophageal squamous cell carcinoma treated with chemotherapy (paclitaxel plus cisplatin) combined with radiotherapy versus chemotherapy alone, and also to evaluate the efficacy and toxicity of the regimen.
  • METHODS: In this prospective and non-randomized study, 47 patients with definite measurable lesion and having no previous chemotherapy were enrolled.
  • After 2-6 cycles of chemotherapy, those who gained CR, PR or SD were non-randomly assinged into radiotherapy group (group A) or non-radiotherapy group (group B).
  • The overall response rate of chemotherapy was 42.6% (95% CI, 0.28-0.58).
  • There were no grade 4 clinical toxicity and treatment-related death in this series.
  • CONCLUSION: The combined therapy using chemotherapy (paclitaxel + cisplatin) followed by radiotherapy is effective, tolerable, and statistically superior to chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fatigue / etiology. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neutropenia / etiology. Paclitaxel / administration & dosage. Prospective Studies. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy, High-Energy / adverse effects. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974288.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA: Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol; 2010 May;5(5):713-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
  • BACKGROUND: Based on the observation of topoisomerase-1, upregulation by mitomycin C (MMC), and the phase I antitumor activity of sequential MMC/irinotecan in esophageal cancer, we conducted a phase II evaluation of two schedules of this combination in previously untreated stage III/IV esophageal/gastroesophageal junction adenocarcinomas.
  • CONCLUSION: Irinotecan/MMC is feasible in esophageal/gastroesophageal junction adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):289-300 [9748633.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 May;63(6):1073-82 [18795290.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Control Clin Trials. 1999 Aug;20(4):343-52 [10440561.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Hum Pathol. 2000 Jun;31(6):631-2 [10872653.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1841-51 [12453851.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Science. 1989 Nov 24;246(4933):1046-8 [2555920.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5919-24 [2168285.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Mol Pharmacol. 1995 May;47(5):907-14 [7538195.001]
  • [Cites] Biochemistry. 1996 May 7;35(18):5778-86 [8639538.001]
  • [Cites] Ann N Y Acad Sci. 1996 Dec 13;803:74-92 [8993502.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4551-6 [18574157.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • (PMID = 20354452.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16059; United States / NCI NIH HHS / CA / R21 CA092956; United States / NCRR NIH HHS / RR / UL1 RR025755; United States / NCI NIH HHS / CA / K12 CA133250; United States / NCI NIH HHS / CA / P30 CA016059; United States / NCI NIH HHS / CA / R21CA92956
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS460376; NLM/ PMC3641556
  •  go-up   go-down


6. Shibata Y, Baba E, Ariyama H, Miki R, Ogami N, Arita S, Qin B, Kusaba H, Mitsugi K, Noshiro H, Yao T, Nakano S: Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. World J Gastroenterol; 2007 Jul 14;13(26):3634-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
  • Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease.
  • We report here a patient with recurrent esophageal BSC, who was successfully treated by systemic chemotherapy containing 5-fluorouracil (5-FU) and cisplatin (CDDP).
  • A 57-year-old woman was diagnosed as having squamous cell carcinoma of the esophagus upon endoscopic examination.
  • The pathological diagnosis of the surgical specimen was BSC.
  • Five months after operation, the patient was diagnosed as having a recurrence of the BSC with metastases to the liver and spleen, and a right paraclavicular lymph node.
  • She was given systemic chemotherapy consisting of continuous infusion of 800 mg/d of 5-FU and 3 h infusion of 20 mg/d of CDDP for 5 consecutive days every 4 wk.
  • The metastatic lesions in the spleen and right paraclavicular lymph node disappeared, and the liver metastasis was apparently reduced in size after 2 courses of chemotherapy.
  • The tumor regression was seen over 6 courses, with progression afterwards.
  • Although subsequent treatment with CPT-11 and CDDP was not effective, docetaxel and vinorelbine temporarily controlled the tumor growth for 2 mo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(2):163-7 [10664341.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2868-71 [10576363.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):120-4 [11755833.001]
  • [Cites] Surg Today. 2003;33(6):444-7 [12768371.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):473-7 [15245779.001]
  • [Cites] Int Adv Surg Oncol. 1980;3:73-109 [6926744.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Acta Pathol Jpn. 1991 Jan;41(1):59-64 [2031457.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(4):273-6 [1537072.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):479-84 [8621231.001]
  • [Cites] Cancer. 1997 May 15;79(10):1871-8 [9149011.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 May;83(5):584-7 [9159819.001]
  • [Cites] Oncol Res. 1997;9(4):167-72 [9268987.001]
  • [Cites] Surg Today. 1997;27(8):685-91 [9306579.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1027-32 [10514383.001]
  • [Cites] Dis Esophagus. 2006;19(6):473-6 [17069591.001]
  • [Cites] Histopathology. 2000 Apr;36(4):331-40 [10759947.001]
  • (PMID = 17659717.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4146806
  •  go-up   go-down


7. Santeufemia DA, Piredda G, Fadda GM, Cossu Rocca P, Costantino S, Sanna G, Sarobba MG, Pinna MA, Putzu C, Farris A: Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse. World J Gastroenterol; 2006 Sep 14;12(34):5565-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.
  • Esophageal cancer (EC) is a highly lethal disease.
  • Approximately 50% of patients present with metastatic EC and most patients with localized EC will have local recurrence or develop metastases, despite potentially curative local therapy.
  • The most common sites of distant recurrence are represented by lung, liver and bone while brain and breast metastases are rare.
  • We report a woman patient who developed breast and brain metastases after curative surgery.
  • We think that in super selected patients with more than one metastasis, when functional status is good and metastases are technically resectable, a surgical excision may be considered as a salvage option and chemotherapy should be delivered to allow a systemic control.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / surgery. Breast Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Metastasis / therapy. Recurrence. Treatment Outcome


8. Seitz JF, Duffaud F, Dahan L, Ries P, Ville E, Laugier R: [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?]. Cancer Radiother; 2001 Nov;5 Suppl 1:107s-112s
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
  • [Transliterated title] Adénocarcinomes du bas oesophage et du cardia: quelle chimiothérapie ou chimioradiothérapie dans le traitement des récidives et des métastases?
  • Adenocarcinomas of esophagus and cardia represent in France approximately 20 to 40% of the esophagus cancers.
  • They have a high risk to develop lymph nodes metastases and liver metastases.
  • Currently, only 50 to 70% of patients may benefit from surgical curative resection at diagnosis, but more than 50% of them will recur.
  • The standard of treatment of these metastatic adenocarcinomas is chemotherapy.
  • Three large randomized comparative studies, between chemotherapy and supportive care, showed that chemotherapy significantly extends the median of survival (from 3-4 months to 10-12 months) and improves the quality of life.
  • New drugs (such as docetaxel, CPT11, oxaliplatin) used alone or in combination, especially with 5U, are very promising.
  • Radio-chemotherapy is the preferred treatment for locoregional recurrences, because it improves dyphagia and enables to obtain complete tumor responses.
  • Current results from concomitant radio-chemotherapy studies for esophagus cancer, based on 5FU alone, 5FU-cisplatin or 5FU-mitomycin, given as preoperative treatment or as exclusive treatment, support to use radio-chemotherapy for the treatment of loco-regional recurrences after surgical resection.
  • Nevertheless, the optimal radio-chemotherapy schedule still remain to be defined (dose, duration, splitting of radiotherapy, choice of anticancer drugs).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cardia / pathology. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Deglutition Disorders / etiology. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Mitomycin / administration & dosage. Neoplasm Metastasis. Randomized Controlled Trials as Topic. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11797269.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Suzuki T, Izumi Y, Miura A, Kato T, Kawada K: [Successful management of the recurrent esophageal cancer following esophagectomy at a different time with combined local treatment of chemoradiotherapy and hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1737-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful management of the recurrent esophageal cancer following esophagectomy at a different time with combined local treatment of chemoradiotherapy and hepatic arterial infusion chemotherapy].
  • A 63-year-old man who underwent radical resection for esophageal cancer (cStage III)was diagnosed with metastasis of the paraaortic lymph node 5 months after the surgery.
  • He was treated with concomitant chemoradiotherapy (CRT)with low-dose FP(5-FU, CDDP)and 60 Gy of irradiation.
  • Seven months later, there was a metastasis to the liver(S4).
  • He received systemic chemotherapy(5-FU, ADR, CDDP: FAP), but it was not effective, so hepatic arterial infusion chemotherapy(FAP)was performed.
  • Hepatic artery infusion therapy( 5-FU 1,000 mg/3.5 h x ADR 10 mg/1 h x CDDP 10 mg/1 h)was given for 1 day at an interval of 2 weeks for 18 months.
  • The recurrent lesion disappeared completely 9 months after beginning hepatic artery infusion therapy.
  • Most cases with recurrent esophageal cancer have multiple metastases, and the treatment is mainly systemic therapy.
  • However, in a patient with recurrent tumors at different times, it is possible to achieve a complete response and long-time survival by local treatment with fewer side effects as in this case.
  • Combined local treatments could be the second treatment option after failed systemic chemotherapy for recurrent tumors in patients with esophageal cancer.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagectomy. Hepatic Artery. Liver Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Time Factors


10. Hu X, Bao Y, Chen YY, Gao JM, Wang WH, Liu Y, He H, Sun ZW, Poudel S, Wang Y, Zhuang TT, Zhang L, Chen M: [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer]. Ai Zheng; 2008 Oct;27(10):1088-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
  • BACKGROUND & OBJECTIVE: Limited small cell lung cancer (SCLC) is sensitive to both radiotherapy and chemotherapy.
  • This study was to analyze the efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy (HART) on limited SCLC, observe treatment-related adverse events and summarize the treatment failure patterns.
  • METHODS: A total of 55 limited SCLC patients were treated with EP regimen as induction chemotherapy, then received radiotherapy, followed with EP regimen as consolidation chemotherapy.
  • As treatment was completed, patients were followed up, the efficacy and toxicities were evaluated.
  • The 1-, 3-, and 5-year overall survival rates were 79.1%, 40.3% and 16.1%, respectively, with the median survival time of 18.7 months.
  • Grade I esophageal stricture was observed in 2 (3.6%) patients.
  • Of the 55 patients, 16 (29.1%) had local/regional recurrence, 21 (38.2%) suffered from distant metastasis.
  • CONCLUSIONS: The toxicities of EP regimen chemotherapy combined with HART are mild to moderate and are tolerable by patients.
  • Local/regional recurrence and distant metastasis are the main reasons of treatment failure.
  • [MeSH-major] Dose Fractionation. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Small Cell Lung Carcinoma / drug therapy. Small Cell Lung Carcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Esophagitis / etiology. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / etiology. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiation Pneumonitis / etiology. Radiotherapy, High-Energy. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851790.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  •  go-up   go-down


11. Honda M, Izumi Y, Miura A, Kato T, Monma K, Funada N: [A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy]. Gan To Kagaku Ryoho; 2008 Apr;35(4):629-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with large liver metastasis successfully treated with FAP therapy].
  • A 70-year-old man with dysphagia was diagnosed as advanced esophageal cancer by a primary doctor, and he was admitted to our hospital for treatment in February, 2004.
  • The pretreatment diagnosis was basaloid squamous carcinoma, Mt area, T4 (aorta) , N2 (No. 107) , M1 (liver), Stage IVb performed systemic chemotherapy by FAP (5-fluorouracil ( 5-FU)+doxorubicin (DXR)+cisplatin (CDDP) ) from March, 2004.
  • After 4 courses, the local tumor almost entirely disappeared, and the liver metastasis was obviously reduced.
  • We continued chemotherapy afterwards.
  • As of March 31, 2007, he had local lesion CR and metastatic lesion PR.
  • It is very important to perform FAP repeatedly, for local and metastatic lesion of esophageal cancer while maintaining the patient's general condition and avoiding adverse events.
  • [MeSH-major] Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Male. Neoplasm Staging


12. Tsujie M, Shibata N, Nomura T, Tanaka T, Morimoto T, Fujita S, Kitani K, Nakahira S, Okuda H, Takeda M: [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy]. Gan To Kagaku Ryoho; 2003 Feb;30(2):271-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with stage IVb small cell carcinoma of the esophagus who survived 23 months after systemic cancer chemotherapy].
  • X-ray barium studies and upper gastrointestinal endoscopic examination revealed an irregular ulcerated lesion in the lower portion of the esophagus, which was diagnosed based on pathology tests as small cell carcinoma.
  • A computed tomography scan showed para-aortic lymph node swelling and multiple liver metastases.
  • Treatment with chemotherapy of CDDP and 5-FU showed clinical complete remission.
  • However, the patient died of paraaortic lymph node metastasis, recurrence of the original lesion, multiple liver metastasis and brain metastasis 23 months after diagnosis.
  • The prognosis of small cell carcinoma of the esophagus is quite unfavorable because of the highly aggressive biological behavior.
  • However, if remission is achieved by chemotherapy as in this case, a better prognosis is possible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Survivors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610878.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen; VP-P protocol
  • [Number-of-references] 14
  •  go-up   go-down


13. Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N, Yamana H: Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus; 2010 Nov;23(8):646-51
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org).
  • Esophageal cancer patients with distant organ metastasis have usually been treated only to palliate symptoms without multimodality therapy.
  • The current study evaluates the role of multimodality therapy in esophageal squamous cell cancer patients with distant organ metastasis.
  • Between February 1988 and January 2007, 80 esophageal squamous cell cancer patients with distant organ metastases were treated at our institution.
  • Multimodality therapy was performed in 58 patients: 43 patients received chemoradiotherapy, 13 underwent surgery followed by chemotherapy and/or radiation therapy, and two received chemotherapy or chemoradiotherapy followed by surgery.
  • Thirteen patients received single-modality therapy; chemotherapy, radiotherapy, or surgery alone.
  • The metastatic organ was the liver (n= 40), the lungs (n= 33), bone (n= 10), and other (n= 6).
  • Nine patients had metastasis in two organs.
  • There was no difference in the median survival among the sites of organ metastasis, lung, liver, or bone (P= 0.8786).
  • The survival of patients treated with multimodality therapy was significantly better than that of the patients who received single-modality therapy or best supportive care alone (P < 0.0001).
  • In patients treated with multimodallity therapy, there was no difference in survival for patients treated with surgery compared with patients treated without surgery (P= 0.1291).
  • However, these results suggested that multimodality therapy could improve survival of the esophageal squamous cell cancer patients with distant organ metastasis.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
  • (PMID = 20545979.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mafune KI, Tanaka Y, Takubo K: Autopsy findings in patients with esophageal carcinoma: comparison between resection and nonresection groups. J Surg Oncol; 2000 Jul;74(3):196-200
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autopsy findings in patients with esophageal carcinoma: comparison between resection and nonresection groups.
  • The prognosis of patients with esophageal cancer is poor, despite attempts at aggressive multimodality treatment.
  • To yield some important information that could help to improve operative methods and multimodality treatments, we compared autopsy findings such as the extent of local and metastatic spread of cancer in resection (n = 33) and nonresection (n = 38) groups of patients who had had esophageal cancer.
  • Residual or recurrent esophageal cancer was identifiable in 71.9% of patients in the resection group and 94.4% of patients in the nonresection group.
  • Local residual cancer was identified much less frequently in the former group than in the latter (21.2% vs. 94.4%) (P < 0.0001).
  • The most frequent mode of metastasis was hematogenous, occurring in 51.5% of the resection cases and 63.9% of the nonresection cases.
  • Lymph-node metastasis was also observed frequently, being present in 51.5% of resection cases and 58.3% of nonresection cases.
  • Serosal dissemination of cancer was found in 36.4% of resection cases and 25.0% of nonresection cases.
  • The low incidence of localized disease suggests that esophagectomy, even though palliative in some cases, is effective as a treatment for esophageal cancer.
  • The high incidence of lymph-node and hematogenous metastasis after esophagectomy implies that more extensive lymph-node dissection and stronger adjuvant chemotherapy might be required.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Autopsy. Cohort Studies. Combined Modality Therapy. Esophagectomy. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10951416.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H: [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1375-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
  • The combination chemotherapy with docetaxel/CDDP/5-FU(DCF)for head and neck squamous carcinoma(SCC) has been widely accepted.
  • It seems quite natural that DCF therapy is expected to be equally effective against esophageal SCC because of their histological similarity.
  • In this report, we present a case of unresectable advanced esophageal SCC with multiple liver metastases which showed remarkable regression by DCF therapy, with relatively slight adverse effects.
  • The patient was a 46-year-old female, who underwent upper gastrointestinal fiber-optic endoscopy for dysphasia and was diagnosed to have upper middle thoracic esophageal SCC.
  • Abdominal CT scan showed multiple liver metastases with para-aortic lymph node involvement.
  • The clinical stage diagnosis was T3N4M1, Stage IVB, obviously non-resectable far-advanced esophageal SCC.
  • Systemic chemotherapy with DCF was started as the initial treatment.
  • The chemotherapy regimen was as follows.
  • Each course was followed by a 23-day drug-free period, and the entire course was repeated every 28 days.
  • Ten cycles of this DCF chemotherapy were carried out.
  • After 8 cycles, the liver metastases were judged as CR and para-aortic lymph nodes showed a partial response(PR)by CT scan.
  • After 10 cycles, all we could detect was a small local recurrence of the primary tumor, which was then treated with chemoradiotherapy at the outpatient clinic.
  • Until this writing, we added 2 more cycles of DCF therapy for the recurrent para-aortic and inguinal lymph node metastasis.
  • We conclude that DCF therapy is potentially very effective for advanced esophageal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Fluorouracil / therapeutic use. Liver Neoplasms / drug therapy. Taxoids / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Esophagoscopes. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed


16. Maeda M, Goto T, Harigai M, Itoh T, Moriki T, Miyashita T: Myocardial metastasis from squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg; 2009 Aug;57(8):440-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial metastasis from squamous cell carcinoma of the esophagus.
  • A 62-year-old woman was admitted to our hospital because of cancer of the middle thoracic esophagus.
  • Histopathological findings resulted in a diagnosis of well-differentiated squamous cell carcinoma staged as pT3N0M0, pStage IIA, with clear surgical margins.
  • Although she had no clinical symptoms, solitary cardiac metastasis located in the ventricular septum close to the apex was detected on the follow-up computed tomography scans during postoperative month 6.
  • Regardless of chemotherapy followed by radiotherapy, she died of the cancer 17 months after the initial operation.
  • An autopsy revealed metastatic lesions to the heart, lungs, kidneys, and liver.
  • There were two metastatic masses in the heart without direct invasion from the outside of the heart.
  • In cases of esophageal cancer, tumor spread to the heart is usually caused by direct invasion; thus, solitary hematopoietic cardiac metastasis is quite rare.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Heart Neoplasms / secondary
  • [MeSH-minor] Aged. Autopsy. Cell Differentiation. Echocardiography. Esophagectomy. Fatal Outcome. Female. Humans. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Myocardium / pathology. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1987 Sep;94(3):447-9 [3626608.001]
  • [Cites] J Thorac Oncol. 2009 Jan;4(1):127-30 [19096320.001]
  • [Cites] Vojnosanit Pregl. 2005 Dec;62(12):915-20 [16375220.001]
  • [Cites] Clin Radiol. 2008 Dec;63(12 ):1297-309 [18996259.001]
  • [Cites] Arch Pathol Lab Med. 1986 May;110(5):371-4 [3516115.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):329-35 [6453643.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):27-34 [17098886.001]
  • [Cites] APMIS. 1989 Nov;97(11):1018-24 [2590533.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):195-201 [3411785.001]
  • [Cites] Arch Surg. 1983 Jan;118(1):117-20 [6848063.001]
  • (PMID = 19779796.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Mizuiri H, Hihara J, Okada M: [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma]. Gan To Kagaku Ryoho; 2009 May;36(5):831-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CDDP+CPT-11 therapy is useful for stage IVb esophageal small cell carcinoma].
  • An esophageal small cell carcinoma was pointed out at another clinic by gastrointestinal fiberscopy.
  • He was diagnosed as esophageal small cell carcinoma with mediastinum lymph node, pancreas and multiple liver metastasis by CT scan.
  • Then he was administered CDDP+CPT-11 therapy.
  • At one cycle after the first infusion therapy, primary tumor, pancreas and liver metastasis were markedly reduced.
  • Five cycles after the first infusion therapy, he was diagnosed with a lymph node recurrence around the pancreas on January 19, 2004.
  • Then we started CBDCA and VP-16 combination therapy as second-line chemotherapy.
  • But obstructive jaundice and skull metastasis occurred, and he died on July 21, 2004.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology
  • [MeSH-minor] Esophagoscopy. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461188.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


18. Tsutsui M, Yoshino S, Sakamoto K, Oka M: [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2351-3
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis].
  • Imatinib is a standard treatment for metastatic GIST.
  • Surgery is an optional treatment for local recurrence and resectable liver metastasis.
  • We report a case of high risk group rectal GIST with local recurrence, liver metastases and mediastinal pleural metastasis.
  • A 63-year-old man underwent a surgery for undifferentiated esophageal cancer and simultaneously was diagnosed a rectal submucosal tumor of 3 cm by digital examination in 2001.
  • After 2 years, he underwent Miles' operation because of an increase of the rectal submucosal tumor.
  • PET-CT and CT pointed out a local recurrence and liver metastases that were resected in 2004.
  • In 2008, he received a resection of mediastinal pleural metastasis.
  • Combined modality therapy with surgery and chemotherapy for the metastatic GIST may contribute to a long-term survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / therapy. Liver Neoplasms / secondary. Piperazines / therapeutic use. Pleural Neoplasms / secondary. Pyrimidines / therapeutic use. Rectal Neoplasms / therapy
  • [MeSH-minor] Administration, Oral. Benzamides. Chemotherapy, Adjuvant. Humans. Imatinib Mesylate. Male. Mediastinum. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037419.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


19. Doki Y, Ishikawa O, Takachi K, Miyashiro I, Sasaki Y, Ohigashi H, Murata K, Yamada T, Noura S, Eguchi H, Kabuto T, Imaoka S: Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg; 2005 Jun;29(6):700-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.
  • The site of surgical failure in cases of thoracic esophageal cancer (TEC) may be affected by the vertical location of the cancer in this longitudinal organ, suggesting the need to select the mode of adjuvant therapy based on location.
  • We classified 501 TECs (92% squamous cell carcinomas) that underwent curative surgery without preoperative treatment as 13% upper thoracic (Ut), 51% middle thoracic (Mt), and 36% lower thoracic (Lt) lesions.
  • Recurrent disease was discovered in 180 (36%) of the patients during a postoperative survey, most frequently in the cervical nodes (19%), liver (18%), abdominal paraaortic nodes (17%), and upper mediastinal nodes (17%).
  • Although postoperative survival rates were similar (5-year survival: Ut 51%, Mt 55%, Lt 54%), the tumor recurrence site was significantly affected by the TEC vertical location, with recurrence in the cervical and upper mediastinal nodes being most frequent for Ut and Mt cases and in the liver and abdominal paraaortic nodes for Lt cases.
  • Insufficient surgical lymph node clearance could be assessed by the recurrence index (RI), defined as the frequency of metastasis at recurrence divided by that at surgery.
  • These findings indicated that regional tumor recurrence, corresponding to the surgical field, was more frequent in the Ut and Mt cases (53% and 51%) than the Lt cases (18%); and distant recurrence was more frequent in the Lt cases (62%) than in Ut or Mt cases (25% and 36%).
  • Thus the vertical location of the thoracic esophageal cancer can be said to affected strongly the site of tumor recurrence after curative surgery.
  • Regional radiotherapy might be expected to have an adjuvant effect on Ut/Mt tumors and systemic chemotherapy on Lt tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Abdomen. Esophagectomy. Humans. Lymph Node Excision. Mediastinum. Neck. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 11):11-8 [14506599.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):340-6 [8605557.001]
  • [Cites] Dis Esophagus. 2001;14(2):98-103 [11553217.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1315-8 [11100340.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Mar;90(3):364-76 [2770680.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):115-20 [12630005.001]
  • [Cites] Recent Results Cancer Res. 2000;155:123-33 [10693246.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):191-6 [11869318.001]
  • [Cites] Surgery. 2001 Nov;130(5):792-7 [11685188.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):46-55 [12908136.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):275-81 [9015170.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):81-7 [12469149.001]
  • [Cites] World J Surg. 1994 Mar-Apr;18(2):266-72 [8042333.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 May;15(3):98-108 [12801045.001]
  • [Cites] Surgery. 2002 Jul;132(1):93-9 [12110801.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):581-7 [11685019.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):232-7 [10989896.001]
  • [Cites] Gan To Kagaku Ryoho. 1995 Sep;22(11):1538-41 [7574753.001]
  • [Cites] Surgery. 2003 Apr;133(4):368-74 [12717353.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Jan;11(1):89-109, viii [11928803.001]
  • [Cites] Am J Surg. 1999 Jun;177(6):503-6; discussion 507 [10414703.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1616-23 [12655517.001]
  • [Cites] Surgery. 2003 May;133(5):479-85 [12773975.001]
  • (PMID = 16078126.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kantarci M, Polat P, Alper F, Eroglu A, Eren S, Okur A, Onbaş O: Comparison of CT and MRI for the diagnosis recurrent esophageal carcinoma after operation. Dis Esophagus; 2004;17(1):32-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of CT and MRI for the diagnosis recurrent esophageal carcinoma after operation.
  • Despite an increase in radical surgery for esophageal carcinoma, many patients continue to develop recurrent disease.
  • Some reports have suggested that recurrent tumors should be treated aggressively with a combination of chemotherapy and radiotherapy.
  • The aim of this study was to assess the comparative utility of computed tomography (CT) and magnetic resonance imaging (MRI) for the evaluation of recurrence after curative resection of cancer of the esophagus and gastroesophageal junction.
  • To maximize survival benefit, detection of tumor recurrence as early and accurately as possible is important.
  • Twenty-three patients who developed recurrent tumors after curative transthoracic esophagogastrectomy for esophageal carcinoma were analyzed retrospectively.
  • Primary tumor recurrence was detected at the anastomosis side in 19 patients (intraluminal mass in 13 and as diffuse or focal wall thickening in six).
  • Distant recurrence was seen in the liver (n = 5), lung (n = 4), bone (n = 3), abdominal lymph node (n = 4), pleural effusion (n = 2) and pericardial effusion (n = 1).
  • CT and MRI were found equal in showing the intraluminal mass, liver metastasis, pleural and pericardial effusion.
  • Thickening of esophageal wall was demonstrated in nine patients using CT, but only seven of these tumor recurrences were confirmed by MRI, the remaining two were related to secondary fibrosis.
  • Both CT and MRI showed diffuse gastric wall thickening determined as false tumor recurrence due to severe gastritis in one case.
  • There were two (50%) false negatives for lung metastasis in MRI and one bone metastasis (33%) false negative in CT.
  • CT was found superior in the demonstration of lung metastasis and MRI was superior in the evaluation of wall thickening and bone metastasis.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 ISDE
  • (PMID = 15209738.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Song Y, Wang LH, He J, Wang JW: [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases]. Ai Zheng; 2009 Mar;28(3):303-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases].
  • BACKGROUND AND OBJECTIVE: The treatment and prognosis of primary esophageal small cell carcinoma (PESC), an uncommon esophageal malignant tumor, have seldom been reported.
  • This study was to analyze the clinical characteristics, treatment and prognosis of PESC.
  • METHODS: Clinical data of 151 patients treated in Cancer Hospital, Chinese Academy of Medical Sciences, from 1982 to 2007 were reviewed.
  • Patients received surgery, chemotherapy and/or radiotherapy.
  • The median survival time was longer in LD patients(12.3 months) than in those underwent local treatment alone (surgery or radiotherapy).
  • CONCLUSIONS: PESC is a malignant tumor with early metastasis and poor prognosis.
  • Combined therapy based on chemotherapy may improve the short term survival of PESC patients.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619447.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Pedrazzani C, Pasini F, Giacopuzzi S, Bernini M, Gabbani M, Grandinetti A, Tomezzoli A, Ruzzenente A, Guglielmi A, de Manzoni G: [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction]. Chir Ital; 2005 Jan-Feb;57(1):9-14
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary results of neoadjuvant treatment of adenocarcinoma of the gastro-esophageal junction].
  • Thirty-three patients enrolled in a dose-finding study and observed at the 1st Division of General Surgery of the University of Verona between January 2000 and October 2003 underwent neoadjuvant chemo-radiotherapy for gastro-oesophageal junction adenocarcinoma (Siewert type I and II).
  • The induction treatment was completed in 97.0% of cases with no treatment-related mortality.
  • After completion of chemo-radiation 30 patients underwent surgery (90.9%) while three patients did not (progression in 2 cases and chemotherapy toxicity in one).
  • Two operated patients did not undergo resection because of liver metastasis at laparotomy (respectability: 84.8%) and 3 more cases had incomplete tumour resection (R0-resectability: 75.8%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832733.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • METHODS: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • Treatment of primary SCC was chemotherapy +/- radiotherapy alone (n = 29), chemotherapy +/- radiotherapy + surgery (n = 15), or surgery alone (n = 8).
  • The median time to recurrence was 9.8 months, and 5-year DFS was 18.6%.
  • Factors associated with reduced DFS were liver tumor size > 5 cm (hazard ratio (HR) = 2.02) and positive surgical margin (HR = 2.33).
  • Risk factors associated with worse overall survival included synchronous disease (HR = 4.09), hepatic metastasis > 5 cm (HR = 1.71) and positive surgical resection margin (HR = 1.83).
  • Long-term survival, however, can be achieved following surgical resection of SCC liver metastasis, especially in patients who present with limited metachronous disease amenable to margin negative resection.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retreatment. United States


24. Li B, Lei W, Shao K, Zhang C, Chen Z, Shi S, He J: Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res; 2007 Aug;17(4):239-42
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and prognosis of primary malignant melanoma of the esophagus.
  • Primary malignant melanoma of the esophagus is an extremely rare but highly aggressive tumor.
  • The preoperative diagnosis is complicated for the lack of specificity.
  • Unfortunately, the prognosis of primary malignant melanoma of the esophagus remains dismal from most literatures.
  • To better understand this special condition, we reviewed the medical records of patients with primary malignant melanoma of the esophagus in our center, retrospectively.
  • Seven cases were seen at Cancer Hospital (Institute) of Chinese Academy of Medical Sciences from 1975 through 2006.
  • Similar to esophageal carcinoma, dysphagia was the most common symptom.
  • Only one patient, however, was pathologically diagnosed as primary malignant melanoma of the esophagus preoperatively.
  • The most common reason for death was metastasis.
  • Four of the six patients had metastasis to the liver, adrenal gland, heart and lymph nodes, respectively.
  • Our data show that primary malignant melanoma of the esophagus is a highly aggressive disease with poor prognosis.
  • Surgery remains the first selected therapy.
  • The role of radiotherapy and chemotherapy in the treatment of primary malignant melanoma of the esophagus is still uncertain.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Esophagectomy. Female. Humans. Immunohistochemistry / methods. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625454.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Mizuuchi Y, Anbe K, Yamagata N, Ohji Y, Kanamoto K, Yao T: [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy]. Gan To Kagaku Ryoho; 2010 Apr;37(4):715-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IVb small cell carcinoma of the esophagus obtained prolonged survival after combined modality therapy].
  • Small cell carcinoma of the esophagus is a relatively rare disease, and its prognosis is quite poor, because of its rapid progression.
  • Upper gastrointestinal endoscopic examination(GIS)revealed an ulcerated lesion in the lower portion of the thoracic esophagus, and we diagnosed small cell carcinoma by a biopsy specimen.
  • A computer tomography scan revealed solitary liver metastasis, and lymph node swelling on the left side of the superior mesenteric artery.
  • So, we started chemotherapy with VP-16 and CDDP, according to a regimen for small cell carcinoma of the lung.
  • After 4 courses of chemotherapy, the primary lesion, liver metastasis, and lymph node swelling had disappeared, so we decided it was a complete response.
  • The patient received 60 Gy radiotherapy in total, and is still alive 6 years after diagnosis without any evidence of recurrence.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biopsy. Combined Modality Therapy. Esophagoscopy. Female. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414033.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K: Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol; 2010 Jan;40(1):17-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug safety profile was consistent with that of a mammalian target of rapamycin inhibitor.
  • One patient with esophageal cancer and one with gastric cancer treated with RAD001 at 10 mg/day showed marked tumor responses.
  • CONCLUSIONS: Treatment of Japanese cancer patients with RAD001 may be undertaken with the expectation that previously determined pharmacokinetic and safety profiles apply.
  • The drug may hold promise for treatment of esophageal and gastric cancer.
  • [MeSH-major] Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / pharmacokinetics. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Aged. Asian Continental Ancestry Group. Colorectal Neoplasms / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Esophageal Neoplasms / drug therapy. Everolimus. Female. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Neoplasm Staging. Stomach Neoplasms / drug therapy. Survival Analysis. Thyroid Neoplasms / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 May;44(7):1022-9 [18375114.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1596-602 [18332467.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):705-12 [18594212.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Ann Clin Lab Sci. 2008 Summer;38(3):195-209 [18715846.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13544-9 [18768809.001]
  • [Cites] Clin Pharmacol Ther. 2001 Sep;70(3):247-54 [11557912.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):847-58 [12944570.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):101-12 [15657358.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1801-7 [15886325.001]
  • [Cites] Transplant Proc. 2006 Apr;38(3):766-70 [16647466.001]
  • [Cites] Laryngoscope. 2006 May;116(5):814-20 [16652094.001]
  • [Cites] Nephrol Dial Transplant. 2006 Jul;21 Suppl 3:iii18-23 [16815852.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2522-30 [17041096.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1065-73 [16969122.001]
  • [Cites] Leukemia. 2007 Feb;21(2):333-9 [17136116.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1803-10 [17230506.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Neuroendocrinology. 2007;85(1):54-60 [17310129.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] Eur Surg Res. 2007;39(6):380-7 [17700025.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):611-21 [17713840.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):892-900 [18245553.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • (PMID = 19783551.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC2800315
  •  go-up   go-down


27. Pratt BL, Greene FL: Role of laparoscopy in the staging of malignant disease. Surg Clin North Am; 2000 Aug;80(4):1111-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of laparoscopy in the staging of malignant disease.
  • Together with the fervor and benefits afforded by laparoscopic therapeutic interventions in the management of patients with benign disease and the diagnostic usefulness in blunt trauma and abdominal pain, awareness has been rekindled regarding the advantages of laparoscopy for the staging of abdominal malignancy.
  • Similarly, it is hoped that the use of systemic chemotherapy will achieve better specificity in cell destruction in patients identified laparoscopically to have uncontained disease in the abdominal cavity.
  • 7), both diagnostic and therapeutic, in the management of patients with abdominal malignancy will be limited only by the creativity and expertise of physicians and instrument makers.
  • [MeSH-major] Laparoscopy. Neoplasm Staging / methods. Neoplasms / pathology
  • [MeSH-minor] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Female. Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Lymphoma / pathology. Lymphoma / surgery. Palliative Care. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Prognosis. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10987027.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 82
  •  go-up   go-down


28. Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T: Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg; 2002;9(4):469-77
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center.
  • BACKGROUND/PURPOSE: Given that the prognosis of patients with hepatocellular carcinoma (HCC) complicating severe cirrhosis remains uncertain, particularly with regard to various therapeutic strategies, we have evaluated the prognosis in a series of patients with homogeneous diagnostic and therapeutic histories.
  • METHODS: From 1990 to 1998, 411 consecutive HCC patients associated with Child class B and class C cirrhosis who did not have lymph node or distant metastasis were treated by partial hepatectomy (PH; n = 48), percutaneous ethanol injection (PEI; n = 105), transcatheter arterial chemoembolization (TACE; n = 189), chemotherapy, or supportive care (chemo/supportive; n = 69).
  • The Cox model, stratified by the treatment groups, was used for multivariate analysis.
  • There were statistically significant differences between the survival times of patients receiving PH or PEI and TACE, as compared with those receiving chemo/supportive care.
  • According to multivariate analysis, the independent predictive survival factors were: albumin level (> or = 3.0 g/dl), esophageal varices (i.e., absence), tumor size (< or = 3.0 cm), tumor number (solitary), and alpha-fetoprotein (AFP) level (<400 ng/ml).
  • For patients with a score of 3 or more, there were no differences among the treatment groups, excluding those with chemo/supportive care.
  • Therefore, the advantages and disadvantages of these therapies regarding tumor size and location should be counterbalanced.
  • In patients with a score of 3 or more, TACE, when possible, could be a first choice because of its applicability and its adjuvant nature with respect to other therapies such as liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Liver Cirrhosis / complications. Liver Neoplasms / mortality
  • [MeSH-minor] Chemoembolization, Therapeutic. Ethanol / therapeutic use. Female. Hepatectomy. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483269.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


29. Huang J, Cai RG, Meng PJ, Zhang MJ, Cui CX, Yang L, Chu DT, Sun Y, Wang JW: [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus]. Zhonghua Zhong Liu Za Zhi; 2004 Dec;26(12):753-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
  • OBJECTIVE: Paclitaxel was used in a phase II trial in combination with cisplatin for esophageal cancer.
  • The anti-tumor response, toxicity and survival of the treated patients were evaluated.
  • METHODS: Thirty patients with advanced, unresectable, or complicated with metastasis were allotted, twenty-seven patients had no prior chemotherapy while 3 patients had received adjuvant chemotherapy.
  • Treatment was recycled every 21 days.
  • The median time to tumor progression was 5.0 months (range, 1 to 23 months).
  • CONCLUSION: The combination of paclitaxel and cisplatin can be considered as a main regimen in the treatment of advanced esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733398.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • In 5 cases the tumors were located in the mid-esophagus, 3 cases in the lower third of the esophagus and 1 case in the upper third.
  • The average length of esophageal involvement was 5 cm.
  • They underwent radical resection, regional lymph node clearance and esophageal-stomach anastomosis in thorax or at neck.
  • Two patients had a stage IIa disease, five had a stage IIb disease, and the other two had a stage III disease of International Union Contrele Cancer (UICC).
  • All of them were histologically and immunohistochemically confirmed SCC of esophagus.
  • Metastasis was present in 7 of 9 adjacent lymph nodes.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • There was no local tumor recurrence in these 6 patients.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


31. Khoury-Helou A, Lozac'h C, Vandenbrouke F, Lozac'h P: [Primary malignant melanoma of the esophagus]. Ann Chir; 2001 Jul;126(6):557-60
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant melanoma of the esophagus].
  • The primary malignant melanoma of the esophagus is a rare tumor.
  • The study aim was to report two cases, one treated by esophagectomy without thoracotomy and the other one by Lewis-Santy type esophagectomy.
  • One died at the 24th month with liver metastases.
  • The other one who had a cervical invaded lymph node, treated by radio-chemotherapy, is actually in complete remission 9 years after the diagnosis.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy / methods. Melanoma / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Thoracotomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11486540.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Javle M, Hsueh CT: Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol; 2009 Feb 23;2:9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
  • The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment.
  • The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen.
  • Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment.
  • Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy.
  • Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit.
  • Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer.
  • The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy.
  • Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer.
  • [MeSH-major] Carcinoma / therapy. Congresses as Topic. Gastrointestinal Neoplasms / therapy. Medical Oncology / trends
  • [MeSH-minor] Biliary Tract Neoplasms / therapy. Chemotherapy, Adjuvant / methods. Chemotherapy, Adjuvant / trends. Humans. Liver Neoplasms / therapy. Neoplasm Metastasis. Neoplasm Staging / methods. Pancreatic Neoplasms / therapy. Societies, Medical

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Ann Surg Oncol. 2012 Jan;19(1):68-74 [21879261.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1210-4 [15277260.001]
  • [Cites] J Biol Chem. 1990 May 15;265(14):7709-12 [2186024.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):394-400 [16421419.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4914-21 [17050875.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):326-31 [17235048.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4557-61 [17876013.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):734-8 [18272912.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5918-22 [19029412.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2598-603 [19164203.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Nucl Med. 2009 Jul;50(7):1036-41 [19525451.001]
  • [Cites] J Clin Oncol. 2010 Jul 20;28(21):3491-7 [20530271.001]
  • [Cites] J Thorac Oncol. 2010 Sep;5(9):1472-6 [20631636.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • (PMID = 19236713.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2654905
  •  go-up   go-down


33. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol; 2004 Jun 15;22(12):2395-403
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
  • PURPOSE: To identify baseline prognostic factors and assess whether pretreatment quality of life (QoL) predicts survival in patients with locally advanced or metastatic esophago-gastric cancer.
  • PATIENTS AND METHODS: Between 1992 and 2001, 1,080 patients were enrolled into three randomized, controlled trials assessing fluorouracil-based combination chemotherapy.
  • All patients were required to complete the European Organization for Research and Treatment of Cancer core QoL questionnaire before random assignment.
  • Four independent poor prognostic factors were identified by multivariate analysis: performance status >or= 2 (hazard ratio [HR], 1.58; 99% CI, 1.25 to 1.98), liver metastases (HR, 1.41; 99%CI, 1.14 to 1.74), peritoneal metastases (HR, 1.33; 99%CI, 1.01 to 1.74) and alkaline phosphatase >or= 100 U/L (HR, 1.41; 99% CI, 1.14 to 1.76).
  • Information from this analysis can be used to aid clinical decision-making, help individual patient risk stratification, and serve as benchmark for the planning for future phase III trials.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Quality of Life. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Factor Analysis, Statistical. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Multivariate Analysis. Neoplasm Metastasis. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197201.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Meta-Analysis; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


34. Nakahara T, Takagi Y, Takemasa K, Mitsui Y, Tsuyuki A, Shigematsu N, Kubo A: Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis. Eur J Gastroenterol Hepatol; 2008 Oct;20(10):1040-4
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therapeutic assessment with fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is sometimes problematic after radiation therapy.
  • A 50-year-old man underwent FDG PET for staging of esophageal cancer.
  • Chemoradiotherapy was delivered concurrently with a radiation field that expanded from the esophagus into the upper stomach to cover metastasis of the gastric wall.
  • The patient also underwent FDG PET 26 days and 4 months after chemoradiotherapy to evaluate the therapeutic effect.
  • Twenty-eight days after chemoradiotherapy, hematochemistry revealed elevated hepatic enzymes and postcontrast computed tomography showed band-like hypoattenuation in the liver with parenchymal swelling corresponding to the radiation field.
  • Follow-up PET 4 months after therapy showed no abnormal uptake in the liver.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Hepatitis / etiology. Liver / metabolism. Positron-Emission Tomography / methods. Radiation Injuries / radionuclide imaging. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dose-Response Relationship, Radiation. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / radiotherapy. Humans. Male. Middle Aged. Neoplasm Staging / methods. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787476.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Taxoids; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 15H5577CQD / docetaxel
  •  go-up   go-down






Advertisement